Futura Medical plc

LSE FUM.L

Futura Medical plc Price to Sales Ratio (P/S) on January 14, 2025: 28.19

Futura Medical plc Price to Sales Ratio (P/S) is 28.19 on January 14, 2025, a -8.97% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Futura Medical plc 52-week high Price to Sales Ratio (P/S) is 42.95 on February 19, 2024, which is 52.34% above the current Price to Sales Ratio (P/S).
Futura Medical plc 52-week low Price to Sales Ratio (P/S) is 25.99 on February 05, 2024, which is -7.80% below the current Price to Sales Ratio (P/S).
Futura Medical plc average Price to Sales Ratio (P/S) for the last 52 weeks is 34.67.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: FUM.L

Futura Medical plc

CEO	Mr. James Henry Barder
IPO Date	July 22, 2003
Location	United Kingdom
Headquarters	Surrey Technology Centre
Employees	12
Sector	Health Care
Industries Pharmaceuticals

Description

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Key trends

Past 5 years